ROCKWELL MEDICAL, INC. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Rockwell Medical (market cap ~$28.7M) entered an Equity and Asset Purchase Agreement to acquire Vantive's hemodialysis concentrates, machines (AK-98), water treatment systems, and related consumables business, plus a 1M sq ft manufacturing campus in Medolla, Italy. Consideration: $125M base ($50M Tranche A term loan at SOFR+550bps, $50M Tranche B term loan at SOFR+700bps, $25M convertible note at 100% premium to 15-day VWAP) plus up to $45M contingent consideration tied to revenue/EBITDA milestones. Closing expected mid-2027. Pro forma combined entity projected $400–450M annual revenue; Vantive's HD machine installed base ~100k units. Rockwell withdraws 2026 guidance due to transaction and financing expenses.
Why this rating
Acquisition price ($125M+ $45M contingent) is 4.4–5.9× company market cap; transforms micro-cap from US-only concentrates supplier into global vertically-integrated platform with manufacturing, recurring consumables revenue, and 100k installed base. Business-changing scale and scope shift.
Price action (we called it positive)
before filing · preread $8.09 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.